This study group aimed to revise the 2017 international consensus guidelines for the
management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas, and …

Abstract Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an
indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker …

Evidence-based guidelines on the management of pancreatic cystic neoplasms (PCN) are
lacking. This guideline is a joint initiative of the European Study Group on Cystic Tumours of …

The management of intraductal papillary mucinous neoplasm (IPMN) continues to evolve. In
particular, the indications for resection of branch duct IPMN have changed from early …

Background & Aims To successfully implement imaging-based pancreatic cancer (PC)
surveillance, understanding the timeline and morphologic features of neoplastic progression …

Background This systematic review aimed to assess the diagnostic accuracy of the
International Consensus Fukuoka Guidelines (ICG2017) in identifying high-risk lesions of …

Context.—Pancreatic cystic lesions (PCLs) are very common, and their detection is
increasing with the advances in imaging techniques. Because of the major implications for …

Abstract Background/Objectives: Intraductal papillary mucinous neoplasms (IPMNs) are a
cystic precursor to pancreatic cancer. IPMNs deemed clinically to be at high-risk for …

Objective: The purpose of this study is to determine preoperative factors that are predictive of
malignancy in patients undergoing pancreatic resection for intraductal papillary mucinous …

Background Although there are numerous reports focusing on surgical indication for
intraductal papillary mucinous neoplasm (IPMN), the recurrence patterns following surgery …